Patents by Inventor Eva Jennische
Eva Jennische has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9962424Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.Type: GrantFiled: October 15, 2015Date of Patent: May 8, 2018Assignee: LANTMÄNNEN AS-FAKTOR ABInventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
-
Publication number: 20160030515Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.Type: ApplicationFiled: October 15, 2015Publication date: February 4, 2016Applicant: LANTMANNEN AS-FAKTOR ABInventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
-
Patent number: 9220750Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.Type: GrantFiled: February 11, 2010Date of Patent: December 29, 2015Assignee: LANTMANNEN AS-FAKTOR ABInventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
-
Patent number: 9000125Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: GrantFiled: May 11, 2012Date of Patent: April 7, 2015Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische
-
Patent number: 8748367Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.Type: GrantFiled: February 26, 2010Date of Patent: June 10, 2014Assignee: AS Faktor ABInventors: Hans-Arne Hansson, Eva Jennische, Stefan Lange, Ivar Lönnroth, Peter Eriksson, Anders Persson
-
Patent number: 8389468Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: GrantFiled: February 11, 2011Date of Patent: March 5, 2013Assignee: Lantmannen AS-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
-
Patent number: 8309513Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: GrantFiled: October 27, 2008Date of Patent: November 13, 2012Assignee: Lantmannen As-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
-
Publication number: 20120283191Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: ApplicationFiled: May 11, 2012Publication date: November 8, 2012Inventors: Hans-Arne HANSSON, Stefan Lange, Eva Jennische
-
Patent number: 8207296Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: GrantFiled: October 27, 2008Date of Patent: June 26, 2012Assignee: Lantmannen AS-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische
-
Publication number: 20120093716Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.Type: ApplicationFiled: February 11, 2010Publication date: April 19, 2012Applicant: LANTMANNEN AS-FAKTOR ABInventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
-
Publication number: 20110305773Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: ApplicationFiled: February 11, 2011Publication date: December 15, 2011Inventors: Hans-Arne HANSSON, Stefan LANGE, Eva JENNISCHE, Tomas BERGSTRÖM
-
Publication number: 20100286052Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.Type: ApplicationFiled: February 26, 2010Publication date: November 11, 2010Applicant: AS FAKTOR ABInventors: Hans-Arne Hansson, Eva Jennische, Stefan Lange, Ivar Lönnroth, Peter Eriksson, Anders Persson
-
Publication number: 20090185982Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: ApplicationFiled: October 27, 2008Publication date: July 23, 2009Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergstrom
-
Publication number: 20090162296Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: ApplicationFiled: October 27, 2008Publication date: June 25, 2009Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische
-
Publication number: 20070009575Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.Type: ApplicationFiled: September 24, 2004Publication date: January 11, 2007Inventors: Hans-Arne Hansson, Eva Jennische, Stefan Lange, Ivar Lonnroth, Peter Eriksson, Anders Persson
-
Publication number: 20020099016Abstract: A new recombinant protein called Antisecretory Factor (rAF) and homologues and peptide fragments thereof are described. The protein and the homologues and fragments thereof are useful for normalising pathological fluid transport and/or inflammatory reactions in animals including humans. Antibodies against AF or homologues or fragments thereof are described. Nucleic acids coding for the protein or for homologues or fragments thereof are also described as well as vectors and hosts comprising the nucleic acids. The rAF and homologues and fragments thereof could be used for immunodetection, as feed additive for growing animals and as antidiarrheal and drugs against diseases involving edema, dehydration and/or inflammation.Type: ApplicationFiled: November 26, 2001Publication date: July 25, 2002Inventors: Ivar Lonnroth, Stefan Lange, Eva Johansson, Eva Jennische, Christina Lonnroth
-
Patent number: 6344440Abstract: A new recombinant protein called Antisecretory Factor (rAF) and homologues and peptide fragments thereof are described. The protein and the homologues and fragments thereof are useful for normalizing pathological fluid transport and/or inflammatory reactions in animals including humans. Antibodics against AF or homologues or fragments thereof are described. Nucleic acids coding for the protein or for homologues or fragments thereof are also described as well as vectors and hosts comprising the nucleic acids. The rAF and homologues and fragments thereof could be used for immunodetection, as feed additive for growing animals and as antidiarrheal and drugs against diseases involving edema, dehydration and/or inflammation.Type: GrantFiled: March 13, 1998Date of Patent: February 5, 2002Assignee: Rural Patent Svenska ABInventors: Ivar Lönnroth, Stefan Lange, Eva Johansson, Eva Jennische, Christina Lönnroth
-
Patent number: 5525593Abstract: The use of IGF-II for preparing a medicament for the regeneration of muscle tissue; and methods for medical treatment for the purpose of regenerating muscle tissue, for minimizing scar formation during healing of a wound or for preventing undesired tissue adhesion after injury, such as after surgery.Type: GrantFiled: January 26, 1994Date of Patent: June 11, 1996Assignee: Pharmacia ABInventors: Mats Lake, Eva Jennische